TNGX Tango Therapeutics Inc

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 1:30 PM ET.

A live webcast of the presentation will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241127715588/en/

Investor Contact: Sam Martin/Andrew Vulis Argot Partners tango@argotpartners.com Media Contact: Amanda Brown Galgay SVP, Corporate Communications, Tango Therapeutics media@tangotx.com

Tango Therapeutics (NASDAQ:TNGX)
過去 株価チャート
から 12 2024 まで 1 2025

Tango Therapeutics (NASDAQ:TNGX)
過去 株価チャート
から 1 2024 まで 1 2025